Movement Alert|Novanta Intraday Rise 5.16% in Regular Trading, earnings beat and Riverpoint acquisition synergy draw focus

Market Focus11-11

On November 11, Novanta rose 5.16% in Regular Trading, trading at $129.81, with turnover of $39.08 million.

The move followed the company’s latest quarterly report, which exceeded market expectations, while investors also focused on contributions from the recently acquired Riverpoint Medical business.

For the quarter ended in early October, Novanta reported adjusted EPS of $1.05 on revenue of $305.0 million, above consensus estimates of $0.97 and $301.0 million, respectively. Revenue increased 23% year over year, with about $32.9 million of contribution tied to Riverpoint Medical consolidation.

Management guided fourth-quarter adjusted EPS to $0.91 to $0.96 on revenue of $306 million to $312 million, while full-year adjusted EPS was set at $3.66 to $3.71 on revenue of $1.135 billion to $1.140 billion. Riverpoint had been presented earlier as immediately accretive to growth, margins, earnings, and cash flow, reinforcing the market’s focus on acquisition synergy.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment